Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
The effect of cell subset isolation method on gene expression in leukocytes.
Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals.
Functional analyses reveal extensive RRE plasticity in primary HIV-1 sequences selected under selective pressure.
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
Development and validation of a quantitation assay for fluorescently tagged HIV-1 virus-like particles.